Santarus to Present at RBC Capital Markets Healthcare Conference

Business Wire, Dec 7, 2006

SAN DIEGO -- Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that Gerald T. Proehl, president and chief executive officer, will participate in a gastroenterology panel discussion at the RBC Capital Markets Healthcare Conference on Wednesday, December 13, 2006 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) at the Westin New York Hotel at Times Square.

Interested investors may gain access to a live audio webcast of the above presentation via the Internet by visiting the Investor Relations section of the company's Web site at www.santarus.com. The presentation will be available on the Santarus Web site for 14 days following the live presentation.

About Santarus

Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that treat gastrointestinal diseases and disorders and enhance the quality of life for patients. The company currently markets ZEGERID([R]) Capsules (launched in late March 2006) and ZEGERID Powder for Oral Suspension. These products are immediate-release formulations of omeprazole, a widely prescribed proton pump inhibitor. More information about Santarus is available on the company's Web site at www.santarus.com.

Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation, difficulties or delays in development, testing, manufacturing and marketing of Santarus' products, and other risks detailed in Santarus' prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Santarus([R]) and ZEGERID([R]) are trademarks of Santarus, Inc.